Petrylak, D. P., Perez-Gracia, J. L., Lacombe, L., Bastos, D. A., Mahammedi, H., Kwan, E. M., … Fizazi, K. (2021). 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 32, pp. S629–S630). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1092

Petrylak, D. P., J. L. Perez-Gracia, L. Lacombe, D. A. Bastos, H. Mahammedi, E. M. Kwan, S. Zschäbitz, et al. “579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 32:S629–30. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1092.

Petrylak DP, Perez-Gracia JL, Lacombe L, Bastos DA, Mahammedi H, Kwan EM, et al. 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). In: Annals of Oncology. Elsevier BV; 2021. p. S629–30.

Petrylak, D. P., et al. “579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S629–30. Crossref, doi:10.1016/j.annonc.2021.08.1092.

Petrylak DP, Perez-Gracia JL, Lacombe L, Bastos DA, Mahammedi H, Kwan EM, Zschäbitz S, Armstrong AJ, Pachynski RK, Goh JC, Burotto M, Gravis G, McCune SL, Vázquez Limón JC, Retz M, Saad F, Amin NP, Li J, Unsal-Kacmaz K, Fizazi K. 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2021. p. S629–S630.